|
Abstract:
|
Acute Myelogenous Leukemia (AML) treatment consists of an induction therapy and a consolidation therapy. The purpose of the induction therapy is to achieve complete remission (CR). But induction therapy may not destroy all the AML cells and a consolidation therapy is needed to kill the remaining cells to prevent relapse. In an AML clinical trial, patients received study infusions placebo (P) or GMCSF following induction chemo. Patients achieving CR received one of two therapies: cytarabine (CTB) or cytarabine + mitoxantrone (CTB+MTX) resulting in treatment regimes GMCSF-CTB, GMCSF-CTB+MTX, P-CTB, and P-CTB+MTX, where for example GMCSF-CTB refers to ``Treat with induction chemo + GM-CSF, follow by cytarabine if achieves CR." The goal is to compare diff regimes and find the best regime that leads to extended survival. Here we discuss methods for comparing different AML treatment regimes.
|
